SemCo Inc Inc., a privately-held company developing novel technology using telomere homolog oligonucleotides, or T-oligos, for the potential treatment or prevention of cancer. The T-oligo technology was developed by Barbara Gilchrest, M.D., Professor and Chair of the Department of Dermatology at Boston University School of Medicine and Chief of Dermatology at Boston Medical Center, and her associates at Boston University. This technology was licensed by Boston University to SemaCo who in turn licensed the technology to cancer therapeutics company CancerVax to develop a technology using telomere homolog oligonucleotides to treat or prevent cancer.
